海洋微生物分子作为潜在的抗炎疗法
Malia Lasalo1, Thierry Jauffrais2, Philippe Georgel3
1Group Bioactivities of Natural Compounds and Derivatives (BIONA), Institut Pasteur of New Caledonia, Member of the Pasteur Network, Noumea 98845, New Caledonia.
Marine drugs
|September 27, 2024
概括
海洋微生物是新型抗炎化合物的丰富来源. 本综述探讨了海洋天然产品 (MNPs) 以及它们在开发新药物以对抗炎症方面的潜力.
科学领域:
- 海洋生物学 海洋生物学
- 药理学 药理学是指药理学的学科.
- 自然产品化学 自然产品化学
背景情况:
- 海洋环境拥有巨大的未开发的生物多样性,具有显著的药理潜力.
- 包括免疫调节剂在内的海洋天然产品 (MNPs) 已被确定,突出显示了它们的治疗前景.
- 海洋微生物是生物活性分子的重要来源,在医学中具有潜在的应用.
研究的目的:
- 审查海洋微生物作为新型抗炎化合物的来源的潜力.
- 描述具有免疫调节潜力的海洋天然产品及其生物标.
- 讨论从海洋微生物中发现抗炎化合物的挑战.
主要方法:
- 关于海洋天然产品及其生物活性的科学出版物的文献综述.
- 对具有免疫调节和抗炎性质的已识别的MNP进行分析.
- 检查相关MNP的生物目标和行动机制.
主要成果:
- 来自海洋微生物的众多MNP表现出显著的免疫调节和抗炎作用.
- 详细介绍了MNP及其向生物通路的具体例子.
- 从海洋微生物来源开发新型抗炎药物的潜力是巨大的.
结论:
- 海洋微生物代表着一个有希望的,但未被充分探索的,用于发现新型抗炎药物的储存库.
- 对MNP的进一步研究可能会导致对炎症性疾病的新治疗策略的开发.
- 克服海洋微生物化合物发现的挑战对于释放这种潜力至关重要.
相关概念视频
Antimicrobial Proteins
947
Antimicrobial proteins are important components of the immune system. They aid the body in combating pathogens by either killing them directly or hindering their replication processes. Four main types of antimicrobial substances are interferons, the complement system, iron-binding proteins, and antimicrobial proteins.
Interferons
Interferons (IFNs) are proteins produced by lymphocytes, macrophages, and fibroblasts infected with viruses. While IFNs cannot prevent viruses from entering and...
Interferons
Interferons (IFNs) are proteins produced by lymphocytes, macrophages, and fibroblasts infected with viruses. While IFNs cannot prevent viruses from entering and...
947
Drugs for Treatment of Ulcerative Colitis in IBD
129
Ulcerative colitis is a chronic inflammatory condition primarily affecting the colon and rectum. The primary drugs used in the treatment of ulcerative colitis are aminosalicylates. They exhibit anti-inflammatory and immunosuppressive properties. They modulate inflammatory mediators and inhibit the activity of nuclear factor κB (NF-κB). Aminosalicylates also reduce inflammation by inhibiting prostaglandin and leukotriene production and decreasing neutrophil chemotaxis and superoxide...
129
MicroRNAs
21.2K
MicroRNA (miRNA) are short, regulatory RNA transcribed from introns—non-coding regions of a gene—or intergenic regions—stretches of DNA present between genes. Several processing steps are required to form biologically active, mature miRNA. The initial transcript, called primary miRNA (pri-mRNA), base-pairs with itself forming a stem-loop structure. Within the nucleus, an endonuclease enzyme, called Drosha, shortens the stem-loop structure into hairpin-shaped pre-miRNA. After...
21.2K
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
119
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
119
Inflammatory Response
1.9K
An inflammatory response is a localized, nonspecific immune reaction that occurs when a tissue is injured. It is characterized by redness, swelling, heat, and pain, which are commonly called the cardinal signs and symptoms of inflammation. Inflammation can sometimes result in a loss of function.
Inflammation can be triggered by various stimuli, such as impact, abrasion, chemical irritation, infections, and extreme hot or cold temperatures. These can damage cells and connective tissue fibers,...
Inflammation can be triggered by various stimuli, such as impact, abrasion, chemical irritation, infections, and extreme hot or cold temperatures. These can damage cells and connective tissue fibers,...
1.9K
Inflammatory Bowel Disease IV: Pharmacological Management
118
Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
Pharmacologic...
118


